Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an intervention integrating contingency management (financial incentives) to enhance hepatitis C treatment uptake following dried blood spot hepatitis C RNA testing among people with recent injecting drug use attending needle and syringe programs: the AMPLIFY study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Contigency Management (Intervention) | Active Comparator |
| |
| Standard of Care (Control) | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Incentive payment | Behavioral | Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing | Data will be presented in percentages and mean (SD) or median values (interquartile range), as appropriate. Chi square test or Fisher's exact test will be utilised, as appropriate, to examine between group differences. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of recruitment through a peer-based referral incentivization scheme | Recruitment numbers | 6 months |
| Time to HCV treatment initiation | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1) Inability or unwillingness to provide informed consent
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will be randomised with a computerised random number generator (or random number table) with block randomisation to assist with keeping participant balance between study arms with a small sample size.
| Time to HCV treatment completion | 6 months |
| Time to visit to confirm viral cure (e.g. sustained virological response, SVR12) | 6 months |
| Participant perceptions and acceptability of being involved in a contingency management study will be assessed by study questionnaire | 6 months |
| Feasibility of a contingency management intervention to enhance hepatitis C treatment uptake | Proportion of participants who enrolled in the study and where assigned treatment who commenced treatment. | 6 months |
| ID | Term |
|---|---|
| D019698 | Hepatitis C, Chronic |
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided